The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report.
Adult
Cell Proliferation
Coculture Techniques
Female
Granulocytes
/ immunology
HLA-DR Antigens
/ metabolism
Humans
Hydrolases
/ immunology
Latent Tuberculosis
/ blood
Lewis X Antigen
/ metabolism
Macrophages
/ immunology
Male
Microbial Viability
/ immunology
Middle Aged
Mycobacterium tuberculosis
/ genetics
Myeloid-Derived Suppressor Cells
/ immunology
Preliminary Data
Sialic Acid Binding Ig-like Lectin 3
/ metabolism
South Africa
/ epidemiology
T-Lymphocytes
/ immunology
Tuberculosis, Pulmonary
/ blood
MDSC
biomarkers
immunology
myeloid derived suppressor cells
tuberculosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
03
2021
accepted:
05
05
2021
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Protective host responses in those exposed to or infected with tuberculosis (TB) is thought to require a delicate balance between pro-inflammatory and regulatory immune responses. Myeloid-derived suppressor cells (MDSCs), regulatory cells that dampen T-cell function, have been described in cancer and other infectious diseases but there are limited data on their role in TB. Peripheral blood was obtained from patients with active pulmonary TB and participants with presumed latent TB infection (LTBI) from Cape Town, South Africa. MDSC frequency was ascertained by flow cytometry. Purified MDSCs were used to assess (i) their suppressive effect on T-cell proliferation using a Ki67 flow cytometric assay and (ii) their effect on mycobacterial containment by co-culturing with H37 MDSCs (CD15 Collectively, these data suggest that circulating MDSCs are induced during active TB disease and can functionally suppress T-cell proliferation and subvert mycobacterial containment. These data may inform the design of vaccines and immunotherapeutic interventions against TB but further studies are required to understand the mechanisms underpinning the effects of MDSCs.
Identifiants
pubmed: 34149712
doi: 10.3389/fimmu.2021.676679
pmc: PMC8207464
doi:
Substances chimiques
CD33 protein, human
0
HLA-DR Antigens
0
Lewis X Antigen
0
Sialic Acid Binding Ig-like Lectin 3
0
Hydrolases
EC 3.-
HsaD protein, Mycobacterium tuberculosis
EC 3.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
676679Informations de copyright
Copyright © 2021 Davids, Pooran, Smith, Tomasicchio and Dheda.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
Immunol Lett. 2014 Mar-Apr;158(1-2):66-72
pubmed: 24333340
Am J Respir Crit Care Med. 2018 Jul 1;198(1):104-116
pubmed: 29425052
BMJ. 2014 Aug 05;349:g4643
pubmed: 25097193
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1053-66
pubmed: 25275852
J Transl Med. 2011 Jun 09;9:90
pubmed: 21658270
Am J Respir Crit Care Med. 2013 Jun 1;187(11):1249-58
pubmed: 23590266
Eur J Immunol. 2017 Jan;47(1):107-118
pubmed: 27861788
J Infect Dis. 2019 Apr 8;219(8):1329-1337
pubmed: 30452655
Semin Immunol. 2014 Dec;26(6):559-77
pubmed: 25311810
Infect Dis Clin North Am. 2016 Jun;30(2):509-522
pubmed: 27208770
J Immunol. 2010 Feb 15;184(4):2038-47
pubmed: 20083674
Am J Respir Crit Care Med. 2013 Sep 15;188(6):724-32
pubmed: 23885784
JAMA. 1994 Mar 2;271(9):698-702
pubmed: 8309034
Lancet. 2013 Mar 23;381(9871):1021-8
pubmed: 23391465
Eur J Immunol. 2010 Nov;40(11):2969-75
pubmed: 21061430
PLoS One. 2015 Apr 16;10(4):e0123772
pubmed: 25879532
Front Immunol. 2018 Oct 23;9:2417
pubmed: 30405617
N Engl J Med. 2019 Dec 19;381(25):2429-2439
pubmed: 31661198